Cambium Bio Limited (ASX:CMB)

Cambium Bio Limited, a clinical-stage regenerative medicine company based in Sydney, announced a successful capital raise of A$1.008 million through the issuance of 2,100,000 new fully-paid ordinary shares at A$0.48 per share. This placement was made to an existing strategic shareholder, Mr. Chun Yi Wu, who increased his stake in the company from approximately 12.25% to 18.5%. The funds raised are part of a broader strategy to finance the pivotal Phase 3 trial of Cambium Bio's product Elate Ocular®, aimed at treating moderate to severe dry eye disease. The raised capital will support the company's ongoing development efforts, and the shares were issued under the company's existing placement capacity without requiring shareholder approval. The CEO of Cambium Bio, Karolis Rosickas, expressed excitement over the continued support from strategic partners and highlighted the growing interest in their novel therapeutic solutions for dry eye disease, which have shown promising efficacy and safety profiles.